EJXB Stock Chart & Stats
€5.14
-€0.09(-1.70%)
At close: 4:00 PM EST
€5.14
-€0.09(-1.70%)
Day’s Range― - ―
52-Week Range€3.73 - €5.81
Previous CloseN/A
Volume0.00
Average Volume (3M)67.00
Market Cap
€1.69B
Enterprise Value€24.54K
Total Cash (Recent Filing)€3.19B
Total Debt (Recent Filing)€7.33B
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Aug 27, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.35
Shares Outstanding368,587,650
10 Day Avg. Volume0
30 Day Avg. Volume67
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.88
Price to Sales (P/S)1.22
P/FCF Ratio8.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.39Price Target Upside-14.68% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering4
EPS Forecast (FY)0.35
Revenue Forecast (FY)€1.56B
Bulls Say, Bears Say
Bulls Say
Recurring Revenue & Installed BaseElekta’s business mixes upfront capital equipment sales with recurring software licenses and long‑term service contracts tied to a large installed base. That installed base supports predictable after‑sales revenue, higher lifetime value and cross‑sell potential, providing durable revenue visibility and resilience over multiple quarters.
Strong Free Cash FlowRobust operating and free cash flow gives Elekta flexibility to service debt, invest in R&D or maintain critical operations despite accounting losses. Sustained cash generation from services and installed systems supports liquidity and reduces near‑term financing risk, a structurally important strength for 2–6 month planning horizons.
Focused Oncology Product PortfolioElekta’s specialized radiation therapy and related software suite address oncology and neurological care, a high‑barrier, regulatory and clinically integrated market. Deep product integration and clinical workflows increase switching costs, sustain aftermarket services demand, and support long sales cycles and durable competitive positioning.
Bears Say
Earnings DeteriorationThe sharp swing to a net loss and materially lower EBIT signals weakened profitability and margin pressure. Persistent earnings volatility can limit reinvestment, constrain discretionary spending and raise questions about recurring margin sustainability absent clear cost or revenue improvements, affecting multi‑quarter operational planning.
Eroding Equity CushionA notable decline in equity reduces the company’s balance‑sheet buffer and increases effective leverage versus prior years. Lower shareholders’ equity limits financial flexibility, raises refinancing and covenant risk if cash flows deteriorate, and weakens resilience to operational shocks over the medium term.
Revenue Contraction TrendNegative revenue growth over recent periods suggests either soft demand or competitive pressures. Continued contraction limits scale advantages, reduces potential for recurring software/service upsell and pressures margins; without new product wins or market expansion, this trend can constrain sustainable top‑line recovery.
Elekta AB News
EJXB FAQ
What was Elekta AB’s price range in the past 12 months?
Elekta AB lowest stock price was €3.73 and its highest was €5.80 in the past 12 months.
What is Elekta AB’s market cap?
Elekta AB’s market cap is €1.69B.
When is Elekta AB’s upcoming earnings report date?
Elekta AB’s upcoming earnings report date is Aug 27, 2026 which is in 28 days.
How were Elekta AB’s earnings last quarter?
Elekta AB released its earnings results on May 28, 2026. The company reported €0.052 earnings per share for the quarter, missing the consensus estimate of €0.13 by -€0.079.
Is Elekta AB overvalued?
According to Wall Street analysts Elekta AB’s price is currently Overvalued.
Does Elekta AB pay dividends?
Elekta AB does not currently pay dividends.
What is Elekta AB’s EPS estimate?
Elekta AB’s EPS estimate is 0.04.
How many shares outstanding does Elekta AB have?
Elekta AB has 368,587,650 shares outstanding.
What happened to Elekta AB’s price movement after its last earnings report?
Elekta AB reported an EPS of €0.052 in its last earnings report, missing expectations of €0.13. Following the earnings report the stock price went down -9.344%.
Which hedge fund is a major shareholder of Elekta AB?
Currently, no hedge funds are holding shares in DE:EJXB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Elekta AB
Elekta AB (publ) operates as a global medical technology company, delivering advanced clinical solutions for managing cancer and various brain disorders. Its extensive oncology offerings include sophisticated radiation therapy systems such as Versa HD, tailored for brain metastases; the groundbreaking Elekta Unity, leveraging MR-Linac technology; linear accelerators like Elekta Harmony; and Elekta Infinity, designed to address diverse radiotherapy needs. The company also provides Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy. Beyond primary treatment devices, Elekta supplies comprehensive treatment management solutions, automated and integrated quality assurance tools, and hardware/software for motion management. Specialized oncology platforms feature MOSAIQ Plaza for multidisciplinary cancer care, the managed hosting service Elekta Axis Cloud, and Elekta Studio for image-guided brachytherapy. Complementary hardware includes the ImagingRing mobile CT scanner. For brachytherapy, they offer smart tools like Oncentra Brachy to streamline repetitive tasks, alongside applicators such as Venezia and Geneva for cervical cancer treatment, and the Elekta Flexitron afterloader for precise workflow execution. In the field of neurosurgery and radiosurgery, Elekta provides the Leksell Gamma Knife series, including Icon for personalized radiation treatment, Perfexion as a vital tool for neurosurgeons, and Lightning for accelerated radiosurgery. Their neurosurgery product line further encompasses the Leksell Vantage Stereotactic System for intracranial procedures and the Leksell Stereotactic System for minimally invasive interventions. Elekta AB (publ) was founded in 1972 and is headquartered in Stockholm, Sweden.
EJXB Stock 12 Month Forecast
Average Price Target
€4.39
▼(-14.68% Downside)
Technical Analysis
Vitrolife AB
―
Camurus AB
―
RaySearch Laboratories AB
―
C-Rad AB Class B
―
MedCap AB
―